Startups love the UK. Its IPO market? Not so much

The UK capital markets present a stark contrast, maintaining its position as Europe's top venture capital destination, attracting $8 billion in H1 and 30% of continental VC capital, while concurrently experiencing its worst IPO fundraising period since 1995, with only five listings raising £160 million in the first half of the year. This decline, underscored by high-profile primary listing shifts like Wise's, is largely attributed by industry leaders to a risk-averse investment culture and structural impediments. While the London Stock Exchange highlights ongoing reforms and a building IPO pipeline, exemplified by Visma's planned listing, the broader outlook remains cautious, emphasizing the urgent need for policy adjustments and increased collaboration to revitalize public markets.

Analysis

The United Kingdom's capital markets present a bifurcated landscape, characterized by a thriving venture capital sector juxtaposed with a moribund public listing environment. The UK remains Europe's undisputed leader for early-stage investment, securing $8 billion for startups in the first half of the year—more than France and Germany combined—and holding its position as the top VC destination for 30 consecutive quarters. However, this private market strength is starkly contrasted by a historic slump in the public markets. Fundraising from London IPOs plummeted to its lowest level since 1995, with only five listings raising a meager £160 million in H1. This malaise is further evidenced by significant blows to the London Stock Exchange's prestige, including Wise's decision to shift its primary listing to the U.S. and reports that pharmaceutical giant AstraZeneca could follow. Industry leaders attribute this decline to a deep-seated, risk-averse investment culture that has prioritized downside protection over growth opportunities, as well as structural issues such as tax schemes that disincentivize growth-stage employees. While LSE leadership insists that reforms have made the market "match fit" and points to a building IPO pipeline, highlighted by the planned listing of Norwegian software firm Visma, the broader outlook remains cautious as the pipeline beyond this single win appears quiet.

Key Decisions for Investors

• Investors should scrutinize UK-listed equities for potential valuation and liquidity headwinds stemming from the prevailing risk-averse sentiment and weak IPO market.
• For those with access to private markets, the UK's robust venture capital performance, which attracted $8 billion in H1, continues to present significant early-stage and growth equity opportunities.
• Monitor the progress of the London Stock Exchange's reform agenda and the materialization of its IPO pipeline beyond the Visma listing, as a failure to attract more high-profile companies will signal persistent structural weaknesses.
• Holders of AstraZeneca (AZN) should closely watch for any definitive news on a potential primary listing move to the U.S., which could impact its index inclusion, liquidity, and investor base.